

August 24, 2018

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai-400051

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 24, 2018 titled "Cadila Healthcare's Biologics manufacturing facility successfully completes USFDA inspection".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

**Cadila Healthcare's Biologics manufacturing facility
successfully completes USFDA inspection**

Ahmedabad, August 24, 2018

Cadila Healthcare Limited announced today that the USFDA inspected its Biologics manufacturing facility (Zydus Biologics) located at the Zydus Biotech Park in Ahmedabad, from 14th August to 24th August 2018. At the end of the inspection, no observation (483) is issued.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.